Could blocking GLP-1 restore the Body's natural defense against low blood sugar?

NCT ID NCT07373236

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at why people with type 1 diabetes lose their natural defense against low blood sugar—the hormone glucagon. Researchers tested whether blocking a hormone called GLP-1 with a drug (exendin(9-39)amide) could restore glucagon release during low blood sugar. Twelve adults with type 1 diabetes took part, receiving either the blocker or a placebo. The goal was to see if this mechanism works in humans, which could lead to new treatments to reduce hypoglycemia risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
exendin(9-39)amide (a GLP-1 blocker)
What this could lead to
If successful, this could point toward a new add-on treatment to insulin therapy that lowers the risk of dangerously low blood sugar in type 1 diabetes.
What could go wrong
This is a very small, early-stage study (12 people) testing a mechanism, not a treatment. Results may not lead to a usable therapy, and the blocker itself may have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Gentofte Hospital

    Hellerup, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.